8-K
false 0001757898 0001757898 2024-08-01 2024-08-01 0001757898 us-gaap:CommonStockMember 2024-08-01 2024-08-01 0001757898 ste:M2.700SeniorNotesDue2031Member 2024-08-01 2024-08-01 0001757898 ste:M3.750SeniorNotesDue2051Member 2024-08-01 2024-08-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 1, 2024

 

 

STERIS plc

(Exact Name of Registrant as Specified in Charter)

 

 

 

Ireland   001-38848   98-1455064
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

70 Sir John Rogerson’s Quay
Dublin 2, Ireland
(Address of Principal Executive Offices)

+353 1 232 2000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Ordinary Shares. $0.001 par value   STE   New York Stock Exchange
2.700% Senior Notes due 2031   STE/31   New York Stock Exchange
3.750% Senior Notes due 2051   ST/51   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


ITEM 5.07.

Submission of Matters to a Vote of Security Holders.

At the 2024 Annual General Meeting of Shareholders (“Meeting”) of STERIS plc (the “Company”) held on August 1, 2024, shareholders voted on the matters specified below, with the final voting results as specified. According to the final report of the inspector of election, there were 98,853,221 Ordinary Shares of the Company outstanding and entitled to vote at the Meeting. There were present at the Meeting, in person or by proxy, the holders of 92,479,253 Ordinary Shares or 93.55% of the outstanding Ordinary Shares of the Company on the record date, constituting a quorum.

 

1.

The shareholders elected the nominees named below to the board of directors of the Company (the “Board”), each for a one-year term, and the results of the vote were as follows:

 

Nominee

   Votes for      Votes
against
     Abstentions      Broker
non-votes
 

Dr. Esther M. Alegria

     87,479,377        1,303,862        42,599        3,653,415  

Richard C. Breeden

     84,174,452        4,489,323        162,063        3,653,415  

Daniel A. Carestio

     87,226,475        1,551,224        48,139        3,653,415  

Cynthia L. Feldmann

     81,958,610        6,825,562        41,666        3,653,415  

Christopher S. Holland

     87,619,989        1,164,660        41,189        3,653,415  

Dr. Jacqueline B. Kosecoff

     84,159,181        4,626,670        39,987        3,653,415  

Paul E. Martin

     87,629,553        1,148,652        47,633        3,653,415  

Dr. Nirav R. Shah

     87,607,353        1,176,588        41,897        3,653,415  

Dr. Mohsen M. Sohi

     81,600,545        7,068,512        156,781        3,653,415  

Dr. Richard M. Steeves

     88,063,034        685,131        77,673        3,653,415  

 

2.

The shareholders approved the proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2025 by the following votes:

 

Votes for

     82,980,785  

Votes against

     9,462,713  

Abstentions

     35,755  

 

3.

The shareholders approved the proposal to appoint Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law to hold office until the conclusion of the Company’s next Annual General Meeting by the following votes:

 

Votes for

     83,078,617  

Votes against

     9,364,485  

Abstentions

     36,151  

 

4.

The shareholders approved the proposal to authorize the Board of the Company or the Audit Committee of the Board to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law by the following votes:

 

Votes for

     91,001,119  

Votes against

     1,438,875  

Abstentions

     39,259  

 

5.

The shareholders approved the proposal to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 12, 2024, by the following votes:

 

Votes for

     82,283,019  

Votes against

     6,478,744  

Abstentions

     64,075  

Broker non-votes

     3,653,415  


6.

The shareholders approved the proposal to the renewal of the Board’s authority to issue authorized but unissued shares under Irish law, by the following votes:

 

Votes for

     91,164,220  

Votes against

     1,255,421  

Abstentions

     59,612  

 

7.

The shareholders approved the proposal to approve the renewal of the Board’s authority to opt-out of statutory pre-emption rights under Irish law regarding the issuance of shares for cash, by the following votes:

 

Votes for

     84,584,590  

Votes against

     7,683,370  

Abstentions

     211,293  


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

STERIS plc
By  

/s/ J. Adam Zangerle

  J. Adam Zangerle
  Senior Vice President, General Counsel and Company Secretary

Dated: August 1, 2024

Shareholder Tools